News

Cerapedics announces i-FACTOR Peptide Enhanced Bone Graft adopted by more than 150 leading U.S. Hospitals

Rapid market adoption highlights advantages of synthetic small peptide technology, one of only two PMA approved bone graft supported by Level 1 human clinical data

Cerapedics announces appointment of Doug Kohrs to board of directors and names Antony Koblish Board Chair

Company announces exhibit at North American Spine Society 2017 annual meeting

Cerapedics Announces Publication of Two­ Year IDE Study Follow Up Data

Results published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years.

Oxford finance provides $20 Million senior debt facility to Cerapedics Inc.

Oxford Finance LLC (“Oxford”), an industryleading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term…

Cerapedics announces breakthrough technology agreement with Premier Inc.

Contract awarded for Breakthrough Technology: Bone Tissue Synthetic Implantable Products

Cerapedics receives Best New Technology Award for Spine Care at NASS Annual Meeting

Award recognizes i-FACTOR™ Peptide Enhanced Bone Graft based on the company’s synthetic small peptide (P-15) technology

Cerapedics announces closing of Series D financing

Funds to support expanded commercialization of i-FACTOR™ Peptide Enhanced Bone Graft

Cerapedics to participate in Canaccord Genuity's Musculoskeletal Conference

Cerapedics receives FDA approval for i-FACTOR Peptide Enhanced Bone Graft in Cervical Spine Surgery

Orthobiologics company positioned to begin commercial distribution in the U.S. following successful Premarket Approval application

Cerapedics announces FDA Advisory Committee Panel Is not required for i-FACTOR PMA Approval

Orthobiologics company has submitted response to remaining items from PMA review of i-FACTOR Peptide Enhanced Bone Graft